Poland· PL-100421193
Waylivra
A volanesorsen product containing volanesorsenum natricum, registered in Poland by Akcea Therapeutics Ireland Ltd.. The same ATC class is registered in 11 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Volanesorsen is registered in 11 of 19 countries.
Countries holding a registration under ATC C10AX18 (volanesorsen), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 7 of them publish a price we can compare per daily dose
Volanesorsen · ATC C10AX18
11 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Spainprice
- United Kingdom
The record
At a glance
URPL (Poland)- Active substance
- Volanesorsenum natricum
- Manufacturer
- Akcea Therapeutics Ireland Ltd.
- Country
- Poland (PL)
- ATC code
- C10AX18
- ATC class
- Volanesorsen
- Defined daily dose
- 20 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Volanesorsen in 5 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SpainWAYLIVRA 285 MG SOLUCION INYECTABLE EN JERINGA PRECARGADAAkcea Therapeutics Ireland Limited
- IcelandWaylivraAkcea Therapeutics Ireland Ltd
- NetherlandsWaylivra 285 mg oplossing voor injectie in voorgevulde spuitAkcea Therapeutics Ireland Ltd
- FranceWAYLIVRA 285 mg, solution injectable en seringue préremplieAKCEA THERAPEUTICS IRELAND (IRLANDE)
- United KingdomWaylivra 285mg/1.5ml solution for injection pre-filled syringesSwedish Orphan Biovitrum Ltd
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/819d86d5-701b-4b2f-8c20-ed9e7dbfab79 GET /v1/drugs/819d86d5-701b-4b2f-8c20-ed9e7dbfab79?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań w ampułko-strzykawce",
"source": "urpl",
"strength": "285 mg",
"packaging": "Rpz ¦ EU/1/19/1360/001 ¦ 132826\n1 amp.-strzyk. \nRpz ¦ EU/1/19/1360/002 ¦ 132827\n4 amp.-strzyk.",
"substance": "Volanesorsenum natricum 285 mg",
"common_name": "Volanesorsenum natricum",
"pl_product_id": "100421193",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about volanesorsen.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.